Articles from Iantrek, Inc.

Six-month data on a new bio-reinforced canaloplasty procedure show 37% IOP reduction; new findings on bio-reinforced cyclodialysis to be presented at AAO 2026

Controlled early clinical adoption begins across select U.S. centers as Iantrek accelerates toward commercialization of its next-generation canal-based restoration technology

AlloFlo™ Uveo expands interventional options for glaucoma surgeons and patients 

Two new milestone publications confirm robust efficacy and safety profile of bio-Interventional uveoscleral outflow enhancement technology

New hope for millions of glaucoma patients as funding advances surgical access to the uveoscleral pathway

CEO Adam Szaronos provides a technology update at the Eyecelerator Conference

White Plains, March 18, 2025 (GLOBE NEWSWIRE) -- Iantrek Announces Positive 2-Year Results Demonstrating Efficacy and Safety of Its Bio-Interventional Technology for Uveoscleral Outflow Enhancement in Glaucoma Patients

WHITE PLAINS, N.Y., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Iantrek, Inc., a medical technology company pioneering bio-interventional approaches for chronic eye diseases, today announced the appointment of Adam Szaronos, as its new Chief Executive Officer. Mr. Szaronos succeeds company founder and innovator Sean Ianchulev, MD, MPH who will remain as Chairman of the Board and Chief Medical Officer.

Super-elastic nitinol filament technology allows surgeons unprecedented access to fully titratable canal intervention

White Plains, Dec. 10, 2024 (GLOBE NEWSWIRE) -- White Plains, NY – December 10, 2024 – Iantrek, Inc., a venture-backed, medical technology company pioneering next-generation bio- and micro-interventional approaches for the treatment of ophthalmic diseases, announced one-year results for the first 100 eyes enrolled in the CREST Registry, a real-world, prospective, observational study evaluating the outcomes of bio-interventional procedures in patients with open angle glaucoma (OAG). The study, titled "One-Year Safety and Effectiveness of Bio-Interventional Cyclodialysis and Scleral Reinforcement in Open-Angle Glaucoma Patients," was recently published in Clinical Ophthalmology, and reported on the safety and effectiveness outcomes of micro-invasive cyclodialysis cleft formation with the CycloPen™ System, followed by scleral reinforcement with AlloFlo™ Bio-Tissue implantation.

WHITE PLAINS, N.Y., Sept. 17, 2024 (GLOBE NEWSWIRE) -- Iantrek, Inc., a venture-backed medical technology company pioneering next-generation bio- and micro-interventional approaches for ophthalmic disease treatment, today announced 1-year results from the company’s prospective multi-center real-world evidence study of open-angle glaucoma patients who underwent uveoscleral outflow enhancement surgery using Iantrek’s interventional cyclodialysis system, combined with adjunct allogeneic bio-tissue reinforcement. Topline results will be presented at the 2024 American Academy of Ophthalmology (AAO) Annual Meeting in Chicago, IL, and the study data has been submitted for peer-reviewed publication.

WHITE PLAINS, N.Y., Sept. 11, 2024 (GLOBE NEWSWIRE) -- Iantrek, Inc., a venture-backed, medical technology company pioneering next-generation bio- and micro-interventional approaches for the treatment of ophthalmic diseases, today announced that clinical results of its uveoscleral outflow technology in 243 eyes with open-angle glaucoma were published in the peer-review Journal of Clinical Medicine. Topline results were presented earlier this year at the 2024 American Society of Cataract and Refractive Surgery Annual Meeting in Boston, MA.

WHITE PLAINS, N.Y., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Iantrek, Inc. announced today that two of its scientific abstract presentations were accepted by the American Academy of Ophthalmology at the upcoming AAO meeting in San Francisco, CA, November 3-6, 2023. These presentations will highlight the clinical results of its CycloPen supraciliary interventional system for suprachoroidal outflow bio-tissue reinforcement as well as a combined dual-outflow trabecular and supraciliary intervention in Open Angle Glaucoma.

WHITE PLAINS, N.Y., Jan. 23, 2023 (GLOBE NEWSWIRE) -- Iantrek today announced the publication of 12-month clinical results of a novel bio-stenting procedure using the company’s microsurgical instrumentation in the prestigious peer-reviewed journal British Journal of Ophthalmology.